Literature DB >> 12127595

Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment.

Jerome A Yesavage1, Ruth O'Hara, Helena Kraemer, Art Noda, Joy L Taylor, Steve Ferris, Marie-Christine Gély-Nargeot, Allyson Rosen, Leah Friedman, Javaid Sheikh, Christian Derouesné.   

Abstract

A number of systems have been proposed for classifying older adults who suffer from cognitive impairment or decline but do not yet meet criteria for Alzheimer's disease (AD). The classification, Mild Cognitive Impairment (MCI), has attracted much attention. It uses relatively specific diagnostic criteria and individuals who meet these criteria appear to be at substantial risk for the development of AD. However, little data is available to define the prevalence of MCI in any age group. We propose a simple mathematical model for the progression of patients from Non-Affected (NA) to MCI to AD. This first-order Markov model defines the likely prevalence of MCI at specific ages. Primary assumptions of the model include an AD prevalence of 1% at age 60 increasing to 25% at age 85 and a conversion rate from MCI to AD of 10% constant across all ages considered. We used the best available information for our model and found (1) that the MCI prevalence increased from 1% at age 60 to 42% at age 85 and (2) that the conversion rate from NA to MCI increased from 1% per year at age 60 to 11% at age 85. In conclusion, this model allows estimation of prevalence of MCI and conversion from NA to MCI based upon known prevalences of AD, conversion rates of MCI to AD, and death rates. Due to its substantial prevalence, MCI may be an important target for screening and possible intervention.

Entities:  

Mesh:

Year:  2002        PMID: 12127595     DOI: 10.1016/s0022-3956(02)00020-1

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  33 in total

Review 1.  The study of Golgi apparatus in Alzheimer's disease.

Authors:  Zhiping Hu; Liuwang Zeng; Zhiling Huang; Jie Zhang; Ting Li
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

2.  Non-homogeneous Markov process models with informative observations with an application to Alzheimer's disease.

Authors:  Baojiang Chen; Xiao-Hua Zhou
Journal:  Biom J       Date:  2011-04-14       Impact factor: 2.207

3.  Effects of advanced aging on the neural correlates of successful recognition memory.

Authors:  Tracy H Wang; Frithjof Kruggel; Michael D Rugg
Journal:  Neuropsychologia       Date:  2009-02-02       Impact factor: 3.139

Review 4.  Structural imaging in early pre-states of dementia.

Authors:  Charles D Smith
Journal:  Biochim Biophys Acta       Date:  2011-07-14

Review 5.  Water Loss in Aging Erythrocytes Provides a Clue to a General Mechanism of Cellular Senescence.

Authors:  Allen P Minton
Journal:  Biophys J       Date:  2020-10-15       Impact factor: 4.033

6.  Effects of problem solving therapy on mental health outcomes in family caregivers of persons with a new diagnosis of mild cognitive impairment or early dementia: a randomized controlled trial.

Authors:  Linda Garand; Donna E Rinaldo; Mary M Alberth; Jill Delany; Stacey L Beasock; Oscar L Lopez; Charles F Reynolds; Mary Amanda Dew
Journal:  Am J Geriatr Psychiatry       Date:  2013-10-08       Impact factor: 4.105

Review 7.  Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective.

Authors:  José Alejandro Luchsinger
Journal:  Eur J Pharmacol       Date:  2008-03-04       Impact factor: 4.432

8.  Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B.

Authors:  Meryl A Butters; William E Klunk; Chester A Mathis; Julie C Price; Scott K Ziolko; Jessica A Hoge; Nicholas D Tsopelas; Brian J Lopresti; Charles F Reynolds; Steven T DeKosky; Carolyn C Meltzer
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

9.  Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.

Authors:  Kuan-Yi Wu; Ing-Tsung Hsiao; Cheng-Sheng Chen; Chia-Hsiang Chen; Chia-Ju Hsieh; Yau-Yau Wai; Chee-Jen Chang; Hsiao-Jung Tseng; Tzue-Chen Yen; Chia-Yih Liu; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04       Impact factor: 9.236

Review 10.  Adiposity, type 2 diabetes, and Alzheimer's disease.

Authors:  José A Luchsinger; Deborah R Gustafson
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.